Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.41 |
| ▸ | BTK | Q06187 | 4/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.41 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 5/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | SCTR | P47872 | 1/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596341 | 0.89 | CSNK1D (0.40) | ABL1BTKCSNK1DCSNK1EFLT3 | |
| SCHEMBL3596346 | 0.80 | NR2F2 (0.44) | ABL1BTKCSNK1DCSNK1ENR2F2 | |
| SCHEMBL6015418 | 0.75 | FLT3 (0.37) | ABL1BTKCSNK1DCSNK1EFLT3 | |
| SCHEMBL4444408 | 0.74 | AXL (0.36) | BTKEGFR | |
| SCHEMBL1590653 | 0.74 | LMNA (0.40) | BTKFLT3EGFRMAPK14 | |
| SCHEMBL3597039 | 0.72 | SYK (0.34) | FLT3 | |
| SCHEMBL1590990 | 0.70 | FLT3 (0.38) | ABL1BTKFLT3 | |
| SCHEMBL3600458 | 0.69 | FLT3 (0.49) | ABL1BTKFLT3EGFR | |
| SCHEMBL4438500 | 0.68 | CSNK1D (0.44) | ABL1CSNK1DCSNK1ENR2F2FLT3 | |
| SCHEMBL10155224 | 0.68 | BTK (0.46) | ABL1BTKCSNK1DCSNK1EEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124637-A1 | Compounds and compositions as inhibitors of receptor tyrosine kinase activity | IRM LLC (BM) | 2005-06-09 | — | — | US | claimed |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| EP-2124954-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008094737-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2008-08-07 | — | — | WO | disclosed |
| EP-1656378-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF RECEPTOR TYROSINE KINASE ACTIVITY | IRM LLC (BM) | 2006-05-17 | — | — | EP | disclosed |
| US-20050124637-A1 | Compounds and compositions as inhibitors of receptor tyrosine kinase activity | IRM LLC (BM) | 2005-06-09 | — | — | US | disclosed |
| WO-2005016528-A2 | 6-SUBSTITUTED ANILINO PURINES AS RTK INHIBITORS | IRM LLC (BM) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124637-A1 | Compounds and compositions as inhibitors of receptor tyrosine kinase activity | BMX, LCK, FYN | ABL1 13/4885BTK 4/4885CSNK1D 812/4885 |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | ADK, PNP, DCK | ABL1 149/4885BTK 381/4885CSNK1D 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.